Skip to main content

Advertisement

SpringerLink
Log in

Cardiac safety of liposomal anthracyclines

  • Published:
Cardiovascular Toxicology Aims and scope Submit manuscript

Abstract

Anthracyclines remain amongst the most active therapeutic agents for breast cancer treatment. Rather than being supplanted by novel targeted agents, they are being combined with them in various schedules. Furthermore, anthracyclines themselves are still being studied, with increasing biological understanding of their biological activity and molecular targets. A cardiac safe formulation of doxorubicin opens a number of interesting therapeutic opportunities. Liposomal doxorubicins appear to provide this opportunity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Knoop, A. S. et al. (2005). Retrospective analysis of topoisomerase IIa amplifications and delections as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. Journal of Clinical Oncology, 23(30), 7483–7490.

    Article  PubMed  CAS  Google Scholar 

  2. Pritchard, K. I., Shepherd, L. E., O’Malley, F. P., Andrulis, I. L., Tu, D., Bramwell, V. H., & Levine, M. N. (2006). National cancer institute of Canada clinical trials group. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. The New England Journal of Medicine, 354(20), 2103–2111.

    Article  PubMed  CAS  Google Scholar 

  3. Slamon D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., & Norton, L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England Journal of Medicine, 344, 783–792.

    Google Scholar 

  4. Swenson, C. E., Bolcsak, L. E., Batist, G., Guthrie, T. H. Jr Tkaczuk, K. H., Boxenbaum, H., Welles, L., Chow, S. C., Bhamra, R., & Chaikin, P. (2003). Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs, 14(3), 239–246.

    Article  PubMed  CAS  Google Scholar 

  5. Overmoyer, B., Silverman, P., Holder, L. W., Tripathy, D., & Henderson, I. C. (2005). Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer. Clinical Breast Cancer, 6(2), 150–157.

    Article  PubMed  CAS  Google Scholar 

  6. Chia, S., Clemons, M., Martin, L. A., Rodgers, A., Gelmon, K., Pond, G. R., & Panasci. L. (2006). Pegylated liposomal doxorubicin and Trastuzumab in Her-2 overexpressing metastatic breast cancer: A multicentre phase II trial. Journal of Clinical Oncology, 24(18), 2773–2778.

    Article  PubMed  CAS  Google Scholar 

  7. Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A, Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer. K., Tkaczuk, K., Park. Y. C., & Lee, L. W. (2001). Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. Journal of Clinical Oncology, 19(5), 1444–1454.

    PubMed  CAS  Google Scholar 

  8. Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N., Welles, L., & Winer, E. (2002). TLC D-99 Study Group. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer, 94(1), 25–36.

    Article  PubMed  CAS  Google Scholar 

  9. Batist, G., Harris, L., Azarnia, N., Lee, L. W., & Daza-Ramirez. P. (2006). Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: Results of a retrospective analysis. Anticancer Drugs, 17(5), 587–595.

    Article  PubMed  CAS  Google Scholar 

  10. Baselga et al. (2005) Phase II trial of Taxol, Trastuzumab plus non-pegylated liposomal doxorubicin in locally advanced and metastatic breast cancer. ASCO.

Download references

Author information

Authors and Affiliations

  1. The Montreal Center for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, The Sir Mortimer B Davis-Jewish General Hospital, McGill University, 3755 Cote Sainte Catherine Road, Montreal, QC, Canada, H3T 1E2

    Gerald Batist

Authors
  1. Gerald Batist
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerald Batist.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Batist, G. Cardiac safety of liposomal anthracyclines. Cardiovasc Toxicol 7, 72–74 (2007). https://doi.org/10.1007/s12012-007-0014-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12012-007-0014-4

Keywords

Search

Navigation